Agilent and Ubix partner to advance targeted cancer therapies in South Korea
You Jae Soo of Agilent Technologies and Seo Bo-Kwang, CEO of Ubix Therapeutics, during the recent MOU signing ceremony in Seoul
Agilent Technologies and Ubix Therapeutics have signed a Memorandum of Understanding (MOU) to accelerate research and development of targeted cancer therapies in South Korea over the next five years.
Under the agreement, the two companies will conduct joint research on targeted protein degradation (TPD) and antibody-drug conjugates (ADC). The collaboration combines Ubix’s proprietary Degraducer anti-cancer drug platform, featuring novel E3 ligase binders, with Agilent’s cancer research expertise and technological capabilities.
Small molecule-induced TPD and ADC are emerging as promising approaches in precision oncology, with the global TPD market projected to reach US$4.37 billion by 2034¹. These methods offer therapeutic potential in previously undruggable molecular spaces, aiming to deliver safer and more effective treatments for difficult targets in the ubiquitin-proteasome pathway (UPP) and ligase complexes.
The partnership taps into Agilent’s advanced technologies, including the InfinityLab Bio LC portfolio, LC/MS systems, and BioTek product lines, to develop efficient analytical methods and workflows that support progress in targeted cancer therapy and immuno-oncology research. This effort supports Ubix’s mission to meet unmet patient needs and expand access to novel treatments that may improve outcomes.
Seo Bo-Kwang, CEO of Ubix Therapeutics, said the collaboration will help deliver next-generation therapies to patients worldwide.
You Jae Soo, South Korea country general manager at Agilent, noted that the partnership demonstrates the confidence local companies place in Agilent’s scientific capabilities.
For more than 25 years, Agilent has invested in South Korea and now employs approximately 400 scientists, engineers, and staff. With a Centre of Excellence Analytical Lab in Seoul, the company has built successful partnerships with leading universities, biomedical firms, and start-ups. Recent collaborations include work with GI Innovation on biomarker testing for the immune-anticancer drug GI-101, and with Theragen Bio to advance bioinformatic solutions for cancer genomic profiling.
Category: Education
